Hot Investor Mandate: Strategic Fund of Biopharma Company Invests Up to $10M in Digital Health Technologies Targeting Oncology and Infectious Diseases

17 Nov

The strategic fund of a biopharmaceutical company based in Western Europe is aligned with the parent company’s strategy, focusing on technology investments related to oncology and infectious diseases. The firm has $150M under management and invests in the range of $1M – $10M per company. The Fund typically makes a first investment at Series A and currently aims to make 1-3 new equity investments a year.

The firm is mainly seeking digital health and healthcare IT investment opportunities at the pre-commercial or commercial stage that will either improve drug development or that will impact the patient journey (e.g., patient monitoring, digital therapeutics, clinical decision support systems) relating to oncology and infectious diseases.

The firm is very active and supportive of its portfolio companies. The Fund typically takes a board seat, and at times also an observer seat. The Fund is looking for management teams experienced in the domain of interest and with entrepreneurial experience.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: